Sunovion announced the nationwide availability of Zetonna (ciclesonide) Nasal Aerosol, 74mcg once-daily, for the treatment of allergic rhinitis (AR), also known as hay fever or nasal allergies.
In three Phase 3 clinical studies including almost 2,500 adults and adolescents ≥12 years of age, Zetonna Nasal Aerosol was shown to significantly improve nasal symptoms of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR).
Patients taking Zetonna reported improved quality of life associated with SAR as measured by the Rhinoconjunctivitis Quality of Life Questionnaire with Standardized Activities (RQLQ[S]), which is based upon evaluation of activity limitation, sleep problems, nose symptoms, eye symptoms, non-nose/eye symptoms, practical problems and emotional function.
Further, patients reported high levels of satisfaction with Zetonna, based on the Regimen Attributes Composite subscale of the Allergic Rhinitis Treatment Satisfaction and Preference (ARTSP) instrument, a patient-reported outcome measure. These data were collected as part of a two-week, randomized, multicenter, two-period study involving 327 patients ≥12 years of age with PAR.
Zetonna is a corticosteroid indicated for the treatment of symptoms associated with SAR and PAR in adults and adolescents ≥12 years of age. Zetonna’s delivery system and once-daily formulation is delivered in a 50mcL spray and provides 24-hour relief. Zetonna uses a hydrofluoroalkane (HFA) propellant and features an easy-to-read, built-in dose indicator so patients can track when their prescriptions should be refilled.
For more information call (800) 739-0565 or visit www.sunovion.com.